CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 10, 2011
Result type: Reports
Project Number: SR0228-000
Product Line: Reimbursement Review

Generic Name: Fingolimod

Brand Name: Gilenya

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Multiple Sclerosis, relapsing-remitting

Indications: Multiple Sclerosis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 16, 2011

Recommendation Type: List with clinical criteria and/or conditions